Original Article

Predictors of Blood Transfusion in Patients Undergoing Cytoreductive Surgeries for Ovarian Malignancy

Authors: Janina V. Pearce, MD, PhD, Jinlei Zhao, PhD, Leslie Randall, MD, MAS, Stephanie A. Sullivan, MD, Devin Miller, MD, Katherine Tossas, PhD

Abstract

Objectives: The aims of this study were to describe the baseline estimated blood loss (EBL) in surgery and transfusion rate in patients undergoing cytoreductive surgeries for ovarian malignancy, and identify perioperative variables associated with blood loss and transfusion.

Methods: A retrospective cohort study at a single institution was performed that included patients with known or suspected ovarian malignancy undergoing cytoreductive surgery between 2016 and 2021. t tests, χ2 tests, and multiple logistic regression analyses were used.

Results: Among 44 patients meeting inclusion criteria, 61% received perioperative blood transfusion. There were significant differences in EBL and preoperative hemoglobin levels between patients who did and did not receive transfusion (EBL 442.6 vs 236.8 mL, P = 0.0008; preoperative hemoglobin 10.2 vs 11.2 g/dL, P = 0.049). After adjusting for preoperative hemoglobin, the risk of transfusion increased for each additional 200 mL of EBL (odds ratio [OR] 3.8, 95% confidence interval [CI] 1.5–9.5). Stratified by race, the association between EBL and transfusion risk remained statistically significant only for non-Latinx White patients (OR 6.1, 95% CI 1.7–21.9), who made up 77% of the study population, but not for patients of other races and ethnicities (OR 1.0, 95% CI 0.16–6.42).

Conclusions: Perioperative blood transfusion is common in patients undergoing cytoreductive surgery. In this study, EBL and preoperative hemoglobin levels were significantly associated with transfusion receipt. Clinicians should optimize hemoglobin levels and intraoperative blood conservation strategies to reduce the need for transfusion. The results also highlight the importance of considering racial and ethnic differences when developing strategies to reduce transfusion risk.
Posted in: Ovarian Disorders And Female Reproductive Health3 Ovarian Disorders3

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. National Cancer Institute. Cancer stat facts: ovarian cancer. https://seer.cancer.gov/statfacts/html/ovary.html. Accessed February 22, 2023.
 
2. National Comprehensive Cancer Network. Ovarian cancer. Including fallopian tube cancer and primary peritoneal cancer. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Published 2021. Accessed February 22, 2023.
 
3. Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621–3627.
 
4. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IVovarian cancer. N Engl J Med 2010;363:943–953.
 
5. Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer 2020;130:114–125.
 
6. Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer 2020; 30:1657–1664.
 
7. Melamed A, Fink G, Wright AA, et al. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasiexperimental study. BMJ 2018;360:j5463.
 
8. Abu-Rustum NR, Richard S, Wilton A, et al. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecol Oncol 2005;99:320–326.
 
9. Black D, Iasonos A, Ahmed H, et al. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer. Gynecol Oncol 2007;107:66–70.
 
10. Zeng Q, Tan S, Bao Q, et al. Intra-operative blood transfusion significantly increases the risk of post-operative pulmonary embolism. J Thorac Dis 2019;11:5566–5571.
 
11. Petrelli F, Ghidini M, Ghidini A, et al. Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis. Surg Today 2021;51:1535–1557.
 .
12. Prescott LS, Vergote I, Sun CC, et al. Transfusion use and effect on progressionfree, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort. Int J Gynecol Cancer 2023;33:1–9.
 
13. Lundin ES, Johansson T, Zachrisson H, et al. Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study. Acta Obstet Gynecol Scand 2014;93:335–344.
 
14. Stanworth SJ, New HV, Apelseth TO, et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol 2020;7:e756–e764.
 
15. Parker WH, Wagner WH. Gynecologic surgery and the management of hemorrhage. Obstet Gynecol Clin North Am 2010;37:427–436.
 
16. Heyns M, Knight P, Steve AK, et al. A single preoperative dose of tranexamic acid reduces perioperative blood loss: a meta-analysis. Ann Surg 2021;273:75–81.
 
17. Kietpeerakool C, Supoken A, Laopaiboon M, et al. Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. Cochrane Database Syst Rev 2016;1:CD011732.
 
18. Altman AD, Liu XQ, Nelson G, et al. The effects of anemia and blood transfusion on patients with stage III-IV ovarian cancer. Int J Gynecol Cancer 2013;23:1569–1576.
 
19. O'Shea A, McCool K, Harrison R, et al. Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer. Gynecol Oncol 2018;150:19–22.
 
20. Zhou J, Ye M, Jiang W, et al. Quantification and influencing factors of perioperative hidden blood loss in patients undergoing laparoscopic ovarian cystectomy for benign ovarian tumours. J Obstet Gynaecol 2022; 42:3181–3186.